GT Biopharma Seeks Approval for 10x Share Increase and 61% Potential Control Shift to Private Placement Investors
GTBP sits 32% above its 52-week low of $4.91.
Summary
GT Biopharma's definitive proxy sets a November 11 vote on a 10x authorized share increase and Nasdaq approval for the September private placement, which could give the investors up to 61% voting control.
Key Events · Corporate Governance and Compliance · GTBP
-
Special Meeting Set for November 11
Stockholders of record as of September 30, 2026 (2,061,052 shares outstanding) will vote on four proposals, including a 10x increase in authorized common shares from 25 million to 250 million.
-
Potential 61% Voting Control Shift
If Proposal 3 is approved and all Series M Preferred converts and all Common Stock Warrants are exercised for cash, the private placement investors would hold approximately 61% of voting power (44% if only preferred converts), constituting a change of control under Nasdaq Rule 5635.
-
Conversion Price Below Current Market
The Series M Preferred Stock and Common Stock Warrants carry a $6.10 conversion/exercise price, subject to a floor of $1.282, versus the current stock price of $6.50.
-
Exchange Cap and Ownership Blocker
Until stockholder approval is obtained, conversions and warrant exercises are capped at the Exchange Cap of 360,695 shares and a 19.99% Beneficial Ownership Limitation.
Analysis · GTBP · Life Sciences
The definitive proxy for the November 11 special meeting quantifies what was previously only outlined: if stockholders approve Proposal 3, the private placement investors from the September 2026 financing could control up to 61% of the company's voting power — a change of control under Nasdaq rules. The proxy also confirms the $6.10 conversion price for the Series M Preferred Stock and warrants, which is below the current $6.50 stock price, and the 10x increase in authorized shares from 25 million to 250 million. Against the backdrop of going-concern doubts and a recent 1-for-25 reverse split, this vote is effectively a referendum on whether the company can access the capital it needs to survive — but at the cost of handing majority control to the financing investors.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 36.5% of the 995 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GTBP was trading at $6.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $4.91 to $28.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.